Mesothelioma - Attorney Mesothelioma Michigan Pleural

All about Mesothelioma - attorney mesothelioma michigan pleural ... Attorney Mesothelioma Michigan Pleural Info. Alaska Mesothelioma Attorney. Arkansas Asbestos Attorney ...

Michigan Mesothelioma Attorneys

Just as Mesothelioma attorneys have specific experience and training, patients seek medical experts who have education and experience focused on this type of cancer. Michigan Mesothelioma attorneys review a patient's records and build a legal case based on the careful and thorough documentation of medical professionals. Although these physicians are not endorsed by this Web site, they do specialize in Mesothelioma treatment and care, evidence that this rare form of cancer requires expert management from medical professionals.

LawInfo Lead Counsel Qualified Mesothelioma Attorneys

W. Roy Smythe, MD
Professor and Chairman/Department of Surgery, Texas A&M University System Health Sciences Center, Scott & White Hospital, Temple, TXPhone: 254-724-2595 Dr. Smythe is currently accruing patients for a protocol involving extrapleural pneumonectomy and Intensity Modulated Radiation Therapy (IMRT).

David C. Rice, MD
Assistant Surgeon and Assistant Professor of Surgery; Director, Mesothelioma Program; Director, Minimally Invasive Surgery Program, Thoracic Surgery/The University of Texas M. D. Anderson Cancer Center, Houston, TXPhone: (713) 794-1477

Dr. Rice is currently concluding enrollment on a Phase II trial of extrapleural pneumonectomy (EPP) followed by Intensity Modulated Radiation Therapy (IMRT). He is also planning a new trial of preoperative Alimta/Cisplatin, followed by EPP and IMRT.

David J. Sugarbaker, MD
Chief, Division of Thoracic Surgery/Brigham and Women's Hospital, Boston, MA Chief, Department of Surgical Services/Dana-Farber Cancer Institute, Boston, MAPhone: (617) 732-6824 Dr. Sugarbaker supports aggressive treatment of pleural mesothelioma. He advocates tri-modal therapy; extrapleural pneumonectomy, chemotherapy and radiation.

Valerie W. Rusch, FACS
Attending Thoracic Surgeon/Memorial-Sloan Kettering Cancer Center, New York, NYPhone: (212) 639-5873 Dr. Rusch is recognized among medical professionals for the treatment of pleural mesothelioma and has written several papers comparing pleural decortication to extrapleural pneumonectomy.

Raja M. Flores, MD
Attending Thoracic Surgeon/Memorial-Sloan Kettering Cancer Center, New York, NYPhone: (212) 639-2806 Dr. Flores works as the Principal Investigator on a clinical trial of neoadjuvant gemcitabine and cisplatin followed by extrapleural pneumonectomy and high dose radiation. He is also involved in a trial of neoadjuvant Alimta/cisplatin, extrapleural pneumonectomy and high dose radiation. He has also compiled a 1,000 patient database to research areas of failure, and how to improve treatments for mesothelioma.

Paul H. Sugarbaker, MD, FACS, FRCS
Director, Surgical Oncology/Washington Cancer Institute, Washington, DCPhone: (202) 877-3908 Dr. Sugarbaker is a specialist in the treatment of peritoneal mesothelioma using a combination of surgery, chemotherapy and radiation.

Brian W. Loggie, MD
Professor of Surgery, Creighton University Medical School; Chief, Division of Surgical Oncology; Director of Cancer Center/Creighton University Medical Center, Omaha, NEPhone: (402) 280-4100 Dr. Loggie specializes in the treatment of peritoneal mesothelioma and peritoneal carcinomatosis. His protocol, based on eligibility, involves surgical debulking in combination with intraperitoneal heated chemotherapy.

Claire F. Verschraegen, MD
Director, Clinical Trial Office and Investigational Drug Program/Cancer Research and Treatment Center, University of New Mexico, Albuquerque, NMPhone: (505) 272-4551Dr. Verschraegen is currently conducting a front-line Alimta/gemcitabine trial for peritoneal mesothelioma patients. She also offers the following Phase I trials for patients who have already been treated with Alimta:

- Phase I Study of Capecitabine with Cisplatin and Irinotecan in Patients with Advanced Malignancies
- Phase I Study of Intravenous TZT-1027 and Gemcitabine, Administered on Day 1 and Day 8 of a Three Week Course in Patients with Advanced Solid Tumors
- Phase I Study of Flavoperidol in Combination with Gemcitabine and Irinotecan in Patients with Metastatic Cancer

David P. Mason, MD
Staff Surgeon, Department of Thoracic and Cardiovascular Surgery/Cleveland Clinic Foundation, Cleveland, OH Phone: (216) 444-4053 Dr. Mason supports the aggressive multimodality therapy for malignant mesothelioma. This includes extrapleural pneumonectomy, chemotherapy and radiation with Intensity Modulated Radiation Therapy (IMRT). Cleveland Clinic Foundation has a multidisciplinary Thoracic Oncology team with extensive experience and clinical trials in the management of malignant mesothelioma.

David M. Jablons, MD
Assistant Professor of Surgery Chief, General Thoracic Surgery/UCSF Mt. Zion Medical Center, San Francisco, CAPhone: (415) 885-3882 Dr. Jablons manages pleural mesothelioma with a radical pleurectomy/decortication and is researching other therapies.

Lary A. Robinson, MD
Director, Division of Cardiovascular and Thoracic Surgery Principal Thoracic Surgical Oncologist/H. Lee Moffitt Cancer Center and Research Institute, Tampa, FLPhone: (813) 972-8412 Dr. Robinson is a member of the multidisciplinary thoracic oncology group at H. Lee Moffitt Cancer Center where he evaluates and treats all stages of mesothelioma. He is also involved in clinical research programs for lung cancer and mesothelioma.

Robert N. Taub, MD
Professor of Clinical Medicine, Columbia University College of Physicians and Surgeons/New York Presbyterian Hospital, New York, NYPhone: (212) 305-4076 Dr. Robert Taub is a medical oncologist and Director of the Connective Tissue Oncology Program at the Herbert Irving Comprehensive Cancer Center and involved in several ongoing multimodality studies of patients with pleural and peritoneal mesothelioma. The Center is located at the Columbia University College of Physicians and Surgeons.

Daniel Sterman, MD
Assistant Professor, Department of Medicine/University of Pennsylvania Medical Center, Philadelphia, PAPhone: (215) 614-0984 Dr. Sterman is the has published several articles on treatment and clinical trials for pleural mesothelioma.

Eric Vallieres, MD
Associate Professor of Surgery, Section of General Thoracic Surgery/University of Washington Medical Center, Seattle, WAPhone: (206) 598-4477 Dr. Vallieres employs a multidisciplinary approach to thoracic malignancies and related clinical trials. Dr. Vallieres co-authored an article on Induction Chemotherapy, Extra Pleural Pneumonectomy And Adjuvant Fast Neutron Radiationtherapy For Pleural Mesothelioma.

Stephen C. Yang, MD
Chief, Division of Thoracic Surgery/Associate Professor of Surgery and Oncology/Surgical Director, Lung Transplantation Program/Director, Thoracic Oncology Program/Johns Hopkins Medical Institutions, Baltimore, MD Phone: (410) 614-3891

Mark J. Krasna, MD
Chief, Division of Thoracic Surgery/University of Maryland School of Medicine; Director, Thoracic Oncology Program/University of Maryland Greenebaum Cancer Center, Baltimore, MDPhone: (410) 328-6366Dr. Krasna has been published extensively on the role of multidisciplinary treatment of lung and esophageal cancers. He is the Principal Investigator of a trimodality treatment protocol for pleural mesothelioma at the University of Maryland. He is also an investigator in intrapleural therapy for mesothelioma.

David H. Harpole, Jr., MD
Associate Professor of Surgery, Thoracic Oncology Program/AssistantProfessor of Pathology, Duke University Medical Center, Durham, NCPhone: (919) 668-8413

Harvey Pass, MD
Karmanos Cancer Institute, Detroit, MIPhone: (313) 745-8746 Dr. Pass is has been recognized around the world for the treatment of mesothelioma, with special expertise in the field of photodynamic therapy, a non-surgical approach.

Gregory P. Kalemkerian, MD
Co-Director of Thoracic Oncology/University of Michigan Comprehensive Cancer Center/Ann Arbor, MIPhone: (734) 936-5281 Dr. Kalemkerian is the director of the multidisciplinary thoracic oncology clinic at the University of Michigan Cancer Center, as well as collaborating with the thoracic oncology team at Karmanos Cancer Institute, to develop innovative clinical trials for mesothelioma patients.

Joseph S. Friedberg, MD
Chief of Thoracic Surgery/University of Pennsylvania at Presbyterian, Philadelphia, PAPhone: (215) 662-9195 Dr. Friedberg is the Principal Investigator on a trial of photodynamic therapy for pleural malignancies, and also on a trial combining Alimta/cisplatin, surgery and XRT.


.